Core Insights - The global blood purification equipment market is projected to grow from USD 17,755.6 million in 2021 to USD 29,242.21 million by 2030, indicating significant market potential for companies in this sector [1]. Company Updates - Aethlon Medical, Inc. is advancing its Hemopurifier® device, which is designed to deplete cancer-promoting exosomes and circulating viruses. The FDA has designated it as a "Breakthrough Device" for treating advanced or metastatic cancer [3][4]. - Aethlon Medical is preparing for phase 1 clinical trials in Australia and India, targeting oncology patients with solid tumors who are not responding to anti-PD-1 monotherapy treatments like Keytruda® or Opdivo® [2][4]. - The company has integrated new in vitro data showing the Hemopurifier's ability to remove exosomes from cancer patient plasma into its clinical trial documentation, which is currently under review by Ethics Committees [2][4]. Financial Performance - CytoSorbents Corporation reported a 14% year-over-year increase in product sales for Q1 2024, reaching USD 9.0 million, the highest in nearly three years. The company also improved its product gross margins to 76% [5]. - Cerus Corporation reiterated its full-year 2024 product revenue guidance range of USD 172 million to USD 175 million, highlighting its ongoing progress in clinical milestones and commercial growth [6][7]. Industry Trends - The blood purification technology sector is gaining attention due to its potential applications in treating various diseases, including cancer and viral infections. Companies like Aethlon Medical are exploring the use of their devices in both oncology and viral disease treatments [11]. - The demand for innovative blood purification solutions is expected to rise, driven by global health challenges and the need for effective treatments against life-threatening conditions [11].

Phase 1 Clinical Trials of the Hemopurifier® Designed to Include Patients With Solid Tumors Who Have Stable or Progressive Disease During Anti-PD-1 Monotherapy Treatment, Such as Keytruda® of Opdivo® Interested Clinical Sites Have Initiated Submissions For Ethics Committee ReviewSAN DIEGO, June 3, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided the following update ...

Core Viewpoint - Aethlon Medical, Inc. has announced a public offering of 8,100,000 shares of common stock and accompanying warrants, priced at $0.58 per share, aiming to raise approximately $4.7 million for general corporate purposes, including clinical trials and research and development [1][2]. Group 1: Offering Details - The public offering includes 8,100,000 shares of common stock and Class A and Class B warrants, all priced at $0.58 per share [1]. - Class A warrants will expire five years after issuance, while Class B warrants will expire one year after issuance [1]. - The offering is expected to close around May 17, 2024, pending customary closing conditions [1]. Group 2: Financial Proceeds - Gross proceeds from the offering are anticipated to be approximately $4.7 million before deducting fees and expenses [2]. - The net proceeds will be utilized for general corporate purposes, which may encompass clinical trial expenses, research and development, capital expenditures, and working capital [2]. Group 3: Company Overview - Aethlon Medical focuses on developing the Hemopurifier, an immunotherapeutic device aimed at treating cancer and life-threatening viral infections [5]. - The Hemopurifier has shown promise in removing life-threatening viruses and harmful exosomes in clinical and pre-clinical studies [5]. - The device has received FDA Breakthrough Device designation for treating advanced or metastatic cancer and life-threatening viruses not addressed by approved therapies [5].

Table of Contents Registration No. 333-278188 As filed with the Securities and Exchange Commission on May 13, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aethlon Medical, Inc. (Name, address, including zip code, and telephone number, including area code, of agent for service) (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) ...

Translational Study Provides Pre-Clinical Evidence to Support The Design of a Phase 1 Study of the Hemopurifier In Cancer Patients With Solid Tumors Treated With Anti-PD-1 Antibodies SAN DIEGO, May 10, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced positive results from an in vitro binding study of its Hemopurifier® in removing extracellular vesicles (EVs) from p ...

Table of Contents Registration No. 333-278188 As filed with the Securities and Exchange Commission on April 25, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 3826 13-3632859 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Id ...

Table of Contents Registration No. 333-278188 As filed with the Securities and Exchange Commission on April 5, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 3826 13-3632859 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Ide ...

Table of Contents Registration No. 333- As filed with the Securities and Exchange Commission on March 22, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 3826 13-3632859 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 1155 ...

Aethlon Medical Will Perform Pre-Clinical Studies to Explore Potential Synergies With its First-in-Class Hemopurifier® Blood Filtration System SAN DIEGO, Feb. 21, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it entered into a Materials Transfer Agreement (MTA) with Santersus AG, a Zurich-London based, privately held therapeutic medical device company, for ...

Financial Data and Key Metrics Changes - As of December 31, 2023, Aethlon Medical had a cash balance of approximately $8 million, with an additional $236,000 raised through common stock sales under the at-the-market program [13] - Consolidated operating expenses for the three months ended December 31, 2023, were approximately $3.6 million, an increase of 25.2% from $2.8 million for the same period in 2022 [14] - The company's net loss increased to $3.6 million for the three months ended December 31, 2023, compared to $2.8 million for the same period in 2022 [17] Business Line Data and Key Metrics Changes - The increase in operating expenses was primarily due to a rise in payroll and related expenses, which increased by approximately $871,000, largely attributed to separation expenses for the former CEO [15] - General and administrative expenses decreased by approximately $92,000, mainly due to a reduction in clinical trial expenses [16] Market Data and Key Metrics Changes - The company is conducting a COVID-19 trial in India with one patient treated to date, and the trial remains open for enrollment as new COVID-19 cases arise [8][31] - The oncology program is set to begin trials in India and Australia, with three interested sites in Australia and one in India awaiting approval from ethics committees [10][11] Company Strategy and Development Direction - Aethlon Medical received clearance from the Drug Controller General of India to conduct a Phase I trial of the Hemopurifier in patients with solid tumors [6] - The focus is on oncology and reducing expenses, with plans to publish articles on preclinical organ transplantation data [9] Management's Comments on Operating Environment and Future Outlook - Management noted that the results from the internal data on the Hemopurifier are inconclusive, prompting engagement with third-party laboratories for independent assays [8] - The company is poised for site activation for oncology trials once in vitro studies are completed, indicating readiness to advance research efforts [11] Other Important Information - The company plans to file its quarterly report on Form 10-Q following the call, with the next earnings call scheduled for June 2024 [17] Q&A Session Summary Question: Will an uptick in COVID cases ease patient enrollment in trials in India? - Management indicated that if critically ill patients are admitted to ICUs, enrollment would be possible [19][21] Question: Are there sufficient Hemopurifiers for clinical efforts? - Management confirmed that there are enough Hemopurifiers for planned oncology trials, but a massive outbreak could pose challenges [22][23] Question: Will there be any one-off costs spilling into the fourth quarter? - Management stated that all one-off costs related to the former CEO's separation have been accrued in the December quarter [24][25] Question: How will patients be involved in the oncology trial? - Plasma samples from cancer patients who have consented will be used for preclinical studies [26][27] Question: How many patients are currently enrolled in the COVID study? - One patient has been enrolled to date, with a maximum of 15 patients allowed in the study [30][31] Question: What is the status of the organ transplant progress? - Management confirmed ongoing collaboration with 34 Life and plans to publish findings from organ transplantation studies [39][40]